CCP
SGNT

Clough Capital Partners’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Clough Capital Partners’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-145,000
Closed -$2.22M – 250
2015
Q3 		$2.22M Buy
+145,000
New +$3.13M 0.1% 126

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clough Capital Partners's SGNT Position: Q4 2015 in Review

Clough Capital Partners sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2015, closing a stake of 145,000 shares — an estimated $2.22M sold.

Clough Capital Partners first reported a position in SGNT in Q3 2015 and held it in 1 quarter. The position peaked at $2.22M in Q3 2015. 134 funds tracked by Wall St. Rank hold SGNT as of Q4 2015.

  • Clough Capital Partners reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2015 after selling out during the quarter.
  • Clough Capital Partners sold 145,000 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2015, an estimated $2.22M.
  • Clough Capital Partners first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2015 and held it in 1 quarter.
  • Clough Capital Partners's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $2.22M in Q3 2015.
  • 134 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2015.

Based on Clough Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.